|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ: Panel members: Strategies for
subtypes - dealing with the diversity of breast cancer: Highlights
of the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giordano S and Columbano A: MicroRNAs: New
tools for diagnosis prognosis, and therapy in HCC? Hepatology.
57:840–847. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sanyal AJ, Yoon SK and Lencioni R: The
etiology of hepatocellular carcinoma and consequences for
treatment. Oncologist. 15(Suppl 4): 14–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kasinski AL and Slack FJ: Epigenetics and
genetics. Histopathology. Nat Rev Cancer. 11:849–864. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: genomics biogenesis,
mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dvinge H, Git A, Gräf S, Salmon-Divon M,
Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, et al:
The shaping and functional consequences of the microRNA landscape
in breast cancer. Nature. 497:378–382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ebert MS and Sharp PA: Roles for microRNAs
in conferring robustness to biological processes. Cell.
149:515–524. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bignell GR, Warren W, Seal S, Takahashi M,
Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, et al:
Identification of the familial cylindromatosis tumour-suppressor
gene. Nat Genet. 25:160–165. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kovalenko A, Chable-Bessia C, Cantarella
G, Israël A, Wallach D and Courtois G: The tumour suppressor CYLD
negatively regulates NF-kappaB signalling by deubiquitination.
Nature. 424:801–805. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lim JH, Jono H, Komatsu K, Woo CH, Lee J,
Miyata M, Matsuno T, Xu X, Huang Y, Zhang W, et al: CYLD negatively
regulates transforming growth factor-beta-signalling via
deubiquitinating Akt. Nat Commun. 3:7712012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tauriello DV, Haegebarth A, Kuper I,
Edelmann MJ, Henraat M, Canninga-van Dijk MR, Kessler BM, Clevers H
and Maurice MM: Loss of the tumor suppressor CYLD enhances
Wnt/betacatenin signaling through K63-linked ubiquitination of Dvl.
Mol Cell. 37:607–619. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pannem RR, Dorn C, Ahlqvist K, Bosserhoff
AK, Hellerbrand C and Massoumi R: CYLD controls c-MYC expression
through the JNK-dependent signaling pathway in hepatocellular
carcinoma. Carcinogenesis. 35:461–468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang WY, Lim JH and Li JD: Synergistic and
feedback signaling mechanisms in the regulation of inflammation in
respiratory infections. Cell Mol Immunol. 9:131–135. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gautheron J and Luedde T: A novel player
in inflammation and cancer: The deubiquitinase CYLD controls HCC
development. J Hepatol. 57:937–939. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Font-Burgada J, Seki E and Karin M: CYLD
and HCC, When being too sensitive to your dirty neighbors results
in self-destruction. Cancer Cell. 21:711–712. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Urbanik T, Köhler BC, Boger RJ, et al:
Down-regulation of CYLD as a trigger for NF-κB activation and a
mechanism of apoptotic resistance in hepatocellular carcinoma
cells. Int J Oncol. 38:121–131. 2011.PubMed/NCBI
|
|
20
|
Hayashi M, Jono H, Shinriki S, et al:
Clinical significance of CYLD downregulation in breast cancer.
Breast Cancer Res Treat. 143:447–457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun SC: CYLD: A tumor suppressor
deubiquitinase regulating NF-kappaB activation and diverse
biological processes. Cell Death Differ. 17:25–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang W, Liu J and Wang G: The role of
microRNAs in human breast cancer progression. Tumor Biol.
35:6235–6244. 2014. View Article : Google Scholar
|
|
23
|
Xia JT, Chen LZ, Jian WH, Wang KB, Yang
YZ, He WL, He YL, Chen D and Li W: MicroRNA-362 induces cell
proliferation and apoptosis resistance in gastric cancer by
activation of NF-κB signaling. J Transl Med. 12:332014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chekulaeva M and Filipowicz W: Mechanisms
of miRNA-mediated posttranscriptional regulation in animal cells.
Curr Opin Cell Biol. 21:452–460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Deng LL, Shao YX, Lv HF, Deng HB and Lv
FZ: Over-expressing CYLD augments antitumor activity of TRAIL by
inhibiting the NF-κB survival signaling in lung cancer cells.
Neoplasma. 59:18–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Massoumi R: CYLD: A deubiquitination
enzyme with multiple roles in cancer. Future Oncol. 7:285–297.
2011. View Article : Google Scholar : PubMed/NCBI
|
